Advertisement

American Journal of Drug Delivery

, Volume 4, Issue 4, pp 249–262 | Cite as

Differentiating factors between oral fast-dissolving technologies

  • Giuseppina Sandri
  • Maria Cristina Bonferoni
  • Franca Ferrari
  • Silvia Rossi
  • Carla CaramellaEmail author
Review Article

Abstract

The oral fast-dissolving systems are defined as oral drug delivery systems that dissolve or disintegrate within a few seconds to a few minutes of placement in the mouth and that do not require water to aid swallowing. Various technologies are used to achieve quick dissolution/dispersion in the oral cavity. This review focuses on the properties of the various fast-dissolving (orally disintegrating) technologies for systemic drug delivery.

Freeze-drying, molding, and compaction technologies are described. Zydis®, Quicksolv® and Lyoc® are prepared by freeze drying; FlashDose® is prepared by a molding/cotton-candy process; WOWTAB®, FlashTab® and Frosta® are prepared by granulation followed by compression; OraSolv®, DuraSolv®, OraVescent®, QDis™, Ziplets® and AdvaTab™ are prepared by direct compression. Differences between drug delivery systems with regard to their composition (excipients), structure and formulation are also reviewed. Employment of relatively consolidated technologies (lyophilization, compaction, and granulation) can shorten the formulation, development, and scaling-up processes. In addition, the properties of systems prepared using these technologies are critically compared. The advantages and the disadvantages of each type of dosage form in terms of dissolution and absorption rate, bioavailability, stability, mechanical strength, taste-masking properties, and patient compliance are emphasized. The implications of these differences for patient compliance and choice of technologies in drug formulation are highlighted.

Freeze-drying allows immediate dissolution of the tablets because of their high porosity, and enhances drug stability, especially for moisture-sensitive substances; on the other hand, a porous network is associated with low physical resistance and high friability, and special packaging is required in some cases. Use of the molding technology results in tablets with an appropriate dissolution time, even though they are characterized by poor mechanical properties (hardness). The fast-dissolving tablets based on compaction technologies utilize consolidated technologies (standard equipment and materials) and their production costs are low. Most of these tablets are characterized by good physical resistance (hardness), although this can result in an increase in the disintegration time.

Apart from its favorable anatomic and physiologic features that allow modulation of drug permeation, the high degree of vascularization, minimal enzymatic pool and potential to avoid first-pass metabolism make the oral cavity an ideal site for peptide/protein delivery and absorption using fast-dissolving formulations. Furthermore, the gentle preparation procedures and technologies (in particular lyophilization) used in the manufacture of oral fast-dissolving tablets are compatible with the delicate drug substances delivered by these formulations.

Keywords

Disintegration Time Direct Compression Tablet Surface Tablet Hardness Buccal Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Rathbone MJ, editor. Oral mucosa drug delivery. New York: Marcel Dekker, 1996Google Scholar
  2. 2.
    Veuillez F, Kalia YN, Jacques Y, et al. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 2001; 51(2): 93–109PubMedCrossRefGoogle Scholar
  3. 3.
    Rossi S, Sandri G, Caramella C. Buccal delivery systems for peptides: recent advances. Am J Drug Deliv 2005; 3(4): 215–25CrossRefGoogle Scholar
  4. 4.
    Song Y, Wang Y, Thakur R, et al. Mucosa drug delivery: membranes, methodologies and application. Crit Rev Ther Drug Carrier Syst 2004; 21(3): 195–256PubMedCrossRefGoogle Scholar
  5. 5.
    Rathbone MJ, Hadgraft J. Absorption of drug from the human oral cavity. Int J Pharm 1991; 74: 9–24CrossRefGoogle Scholar
  6. 6.
    APS JKM, Martens LC. Review: the physiology of saliva and transfer of drugs in to saliva. Forensic Sci Int 2005; 150(2–3): 119–31PubMedCrossRefGoogle Scholar
  7. 7.
    Smart JD. Recent developments in use of bioadhesive systems for delivery of drugs to oral cavity. Crit Rev Ther Drug Carrier Syst 2005; 21(4): 319–44CrossRefGoogle Scholar
  8. 8.
    Rossi S, Sandri G, Caramella C. Buccal drug delivery: a challenge already won? Drug Discov Today: Technologies 2005; 2(1): 59–65CrossRefGoogle Scholar
  9. 9.
    Sharma K, Pfister WR, Ghosh TK. Quick-dispersing oral drug delivery systems. In: Ghosh TK, Pfister WR, editors. Drug delivery to the oral cavity: molecules to market. Volume 145, Chapter 11. Drugs and pharmaceutical sciences series. New York: Marcel Dekker, 2005: 261–99Google Scholar
  10. 10.
    Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21(6): 433–46PubMedCrossRefGoogle Scholar
  11. 11.
    Ghosh TK, Chatterjee DJ, Pfister WR, et al. Quick dissolving oral dosage forms: scientific and regulatory considerations from a clinical pharmacology and biopharmaceutical perspective. In: Ghosh TK, Pfister WR, editors. Drug delivery to the oral cavity: molecules to market. Volume 145, Chapter 14. Drugs and pharmaceutical sciences series. New York: Marcel Dekker, 2005: 337–55CrossRefGoogle Scholar
  12. 12.
    Kearney P. The Zydis oral fast dissolving dosage form. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. Volume 126, Chapter 115. Drugs and pharmaceutical sciences series. New York: Marcel Dekker, 2003: 191–201Google Scholar
  13. 13.
    Gregory GK, Peach TM, Mayne JD. Articles for carrying chemicals. US patent 4371516. 1983Google Scholar
  14. 14.
    Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst 2000; 17(1): 61–72PubMedCrossRefGoogle Scholar
  15. 15.
    Jain RA, Ruddy SB, Cumming KI, et al. Rapidly disintegrating solid oral dosage form. US patent 6316029. 2001Google Scholar
  16. 16.
    Gole DJ, Levinson RS, Wilkinson PK, et al. Pharmaceutical and other dosage forms. US patent 5558880. 1996Google Scholar
  17. 17.
    Mizumoto T, Masuda Y, Fukui M. Intrabuccally dissolving compressed moldings and production process thereof. US patent 5576014. 1996Google Scholar
  18. 18.
    Takaishi Y, Mizumoto T, Masuda Y. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof. US patent 6872405. 2005Google Scholar
  19. 19.
    Pather SI, Khakari R, Siebert J. Quick dissolving intraoral tablets. In: Ghosh TK, Pfister WR, editor. Drug delivery to the oral cavity: molecules to market. Volume 145, Chapter 14. Drugs and pharmaceutical sciences series. New York: Marcel Dekker, 2005: 291–309Google Scholar
  20. 20.
    Pather SI, Rajendra KK, Moe DV. Orasolv and Durasolv: efficient technologies for the production of orally disintegrating tablets. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. Volume 126, Chapter 16. Drugs and the pharmaceutical sciences series. New York: Marcel Dekker, 2003: 203–18Google Scholar
  21. 21.
    Eichman JD, Robinson JD. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998; 15(6): 925–30PubMedCrossRefGoogle Scholar
  22. 22.
    Cardinal Health, Pharmaceutical Technologies and Services. Drug delivery [online]. Available from URL: http://www.cardinal.com/pts/content/delivery/ddoral-zydis.asp [Accessed 2006 May 15]
  23. 23.
    Dobetti L. Fast disintegrating tablets. US patent 6596311. 2003Google Scholar
  24. 24.
    Hayakawa E, Ishikawa Y, Goto T, et al. Tablet manufacturing method and tablet. US patent 6964779. 2003Google Scholar

Copyright information

© Adis Data Informotion BV 2006

Authors and Affiliations

  • Giuseppina Sandri
    • 1
  • Maria Cristina Bonferoni
    • 1
  • Franca Ferrari
    • 1
  • Silvia Rossi
    • 1
  • Carla Caramella
    • 1
    Email author
  1. 1.Department of Pharmaceutical Chemistry, School of PharmacyUniversity of PaviaPaviaItaly

Personalised recommendations